Physician profile
Christopher D Perry
NPI 1437261559
$6,626.91
in general payments reported to CMS, 2019-2025
41 companies · $450 in 2025
The $450 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,502 · 2020: $237 · 2021: $180 · 2022: $1,372 · 2023: $1,338 · 2024: $1,547 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,335.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,287.06 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $718.07 | 2019-2024 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.91 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $481.14 | 2019-2024 | Dupixent |
| Genzyme Corporation | $359.12 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $305.85 | 2019 | |
| Boston Scientific Corporation | $288.88 | 2025 | Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $254.96 | 2019-2024 | |
| Insmed, INC. | $247.59 | 2019-2025 | Arikayce |
| Electromed, INC. | $243.43 | 2019-2024 | Smartvest |
| United Therapeutics Corporation | $219.31 | 2020-2024 | Tyvaso |
| Mylan Specialty L.P. | $197.94 | 2019-2023 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $191.36 | 2019-2024 | Opsumit, Uptravi |
| Genentech USA, INC. | $124.41 | 2019-2023 | Xolair |
| Philips North America LLC | $115.05 | 2020-2024 | (Ak6) Vest Therapy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $114.34 | 2019-2025 | Keytruda, Winrevair |
| Grifols USA, LLC | $110.63 | 2019-2023 | Xembify, Prolastin-C Liquid |
| Amgen INC. | $95.61 | 2022-2023 | Tezspire |
| Jazz Pharmaceuticals INC. | $87.85 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.72 | 2019-2024 | |
| Axsome Therapeutics, INC. | $65.51 | 2023 | Sunosi |
| Verona Pharma, INC. | $59.13 | 2025 | Ohtuvayre |
| Avadel Cns Pharmaceuticals, LLC | $58.45 | 2023-2024 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $48.90 | 2023 | Glassia |
| Abbott Laboratories | $48.22 | 2020-2025 | Jot Dx |
| Gilead Sciences, INC. | $44.39 | 2022 | |
| Pfizer INC. | $31.38 | 2019-2024 | |
| Mallinckrodt Enterprises LLC | $26.88 | 2019 | |
| Csl Behring | $25.58 | 2022 | |
| Pulmonx Corporation | $21.85 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Azurity Pharmaceuticals, INC. | $20.35 | 2024 | Horizant |
| Circassia INC. | $18.39 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.83 | 2019 | |
| Shire North American Group INC | $17.72 | 2019 | |
| Harmony Biosciences LLC | $16.57 | 2025 | |
| Paratek Pharmaceuticals, INC. | $14.90 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.00 | 2022 | |
| Resmed Corp | $12.59 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.78 | 2022 | |
| Advanced Respiratory, INC | $11.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Perry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.